Page 102 - Haematologica May 2022

J.I. Zwicker et al.
JIZ and DP drafted the manuscript. All authors reviewed, pro- vided substantive comments and approved the manuscript.
Acknowledgments
The authors would like to thank the patients and their families, the investigators, and the site personnel who participated in this study. Editorial support was provided by Amanda M. Kelly (Incyte
Corporation); formatting and copyediting assistance was provided by Envision Pharma Group and funded by Incyte Corporation.
Data sharing statement
De-identified patient-level data pertaining to these analyses are available upon reasonable request. Proposals for data access should be sent to datasharing@incyte.com.
References
1. Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1(1):97-105.
2. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350 (2):114-124.
3. Kreher S, Ochsenreither S, Trappe RU, et al. Prophylaxis and management of venous thromboembolism in patients with myelo- proliferative neoplasms: consensus state- ment of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol. 2014;93(12):1953-1963.
4. Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic patients with myelopro- liferative neoplasms: risk-stratified compar- ison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94(4):599-610.
5. De Stefano V, Ruggeri M, Cervantes F, et al. High rate of recurrent venous thromboem- bolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia. 2016;30 (10):2032-2038.
6. Hernández-Boluda J, Arellano-Rodrigo E,
Cervantes F, et al. Oral anticoagulation to prevent thrombosis recurrence in poly- cythemia vera and essential thrombo- cythemia. Ann Hematol. 2015;94(6):911- 918.
7. De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: inci- dence, risk factors, and effect of treatments. Haematologica. 2008;93(3):372-380.
8. Grunwald MR, Stein BL, Boccia RV, et al. Clinical and disease characteristics from REVEAL at time of enrollment (baseline): prospective observational study of patients with polycythemia vera in the United States. Clin Lymphoma Myeloma Leuk. 2018;18(12):788-795.e2.
9. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. 2010. https://evs.nci.nih.gov/ftp1/CTCAE/CTC AE_4.03/CTCAE_4.03_2010-06- 14_QuickReference_8.5x11.pdf. Accessed 25 June 2020.
10.Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombo- cythemia: analysis of the prospective PT1 cohort. Blood. 2012;120(7):1409-1411.
11.Flaker GC, Gruber M, Connolly SJ, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of
stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) tri- als. Am Heart J. 2006;152(5):967-973.
12. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coro- nary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509-1524.
13. Kaifie A, Kirschner M, Wolf D, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-reg- istry. J Hematol Oncol. 2016;9:18.
14.Barbui T, De Stefano V, Falanga A, et al. Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: a consensus-based position paper. Blood Cancer J. 2019;9(8):61.
15. Schulman S and Kearon C, on behallf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738.
16.
1110
haematologica | 2022; 107(5)